[i] Marcellin P, Lau GKK, Bonino F, et al. The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) [PEGASYS(R)] sustain responses 2 years post-treatment. Presented at 41st Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, 26-30 April, 2006.
BASILEA, Suiza, April 28 /PRNewswire/ --
[ii] Lau GKK, Piratvisuth T, Luo K-X et al. Durability of response and occurrence of late response to peginterferon alfa-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B. Presented at 41st Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, April 26-30, 2006.
BASILEA, Suiza, April 28 /PRNewswire/ --
[iii] Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25(3):472-89.
BASILEA, Suiza, April 28 /PRNewswire/ --
[iv] Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32(4 Pt 1):803-6.
BASILEA, Suiza, April 28 /PRNewswire/ --
[v] Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38(5) :1267- 73.
BASILEA, Suiza, April 28 /PRNewswire/ --
[vi] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352(26):2673-81.
BASILEA, Suiza, April 28 /PRNewswire/ --
[vii] Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33(6):1527-32.
BASILEA, Suiza, April 28 /PRNewswire/ --
[viii] Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients: increasing serologic, virologic and biochemical response over time. Hepatology 2004;40 (4 (Suppl 1)):655A.
BASILEA, Suiza, April 28 /PRNewswire/ --
Contacto: Janet Kettels, Roche, +41-79-597-82-85 (móvil). Rachel Morris, Axon Communications, +44-208-822-6759; James Smith (en sitio), Axon Communications, +44-208-822-6692
